検索対象:     
報告書番号:
※ 半角英数字
 年 ~ 
 年

Implications of radiation microdosimetry for accelerator-based boron neutron capture therapy; A Radiobiological perspective

加速器型ホウ素中性子捕獲法におけるマイクロドシメトリの意味; 放射線生物学的展望

福永 久典*; 松谷 悠佑; 徳植 公一*; 大村 素子*

Fukunaga, Hisanori*; Matsuya, Yusuke; Tokuue, Koichi*; Omura, Motoko*

ホウ素中性子捕獲療法(BNCT)は、癌細胞を選択的に照射し、正常細胞の損傷を抑制できる放射線療法として注目を集めている。BNCTの基本概念が1930年代に開発されて以降、現在までに多数の生物実験ならびに臨床応用への向けた橋渡し研究が実施されてきた。最近、医療機関に設置できるBNCT用の中性子加速器が開発されているため、近い将来に、BNCTは世界中の医療機関で利用可能になると予想されている。このような背景から、本稿では、細胞スケールで不均一なエネルギー付与分布を与えるBNCTにおいて、微視的な線量付与の特性が細胞応答(腫瘍殺傷効果)に与える影響について議論する。また、ホウ素剤を用いたBNCTの技術を陽子線治療へ応用する新たな治療法の開発も検討されている。ここで開設するBNCTおよび関連技術の分野の放射線生物学研究は、臨床腫瘍学の分野で広く相乗効果を生み出すことが期待される。

Boron neutron capture therapy (BNCT) has attracted attention as a selective treatment approach for cancer cells while sparing surrounding normal cells. The basic concept of BNCT was developed in the 1930s, but it has not yet been commonly popular in clinical practice, even though there is now a large number of experimental and translational studies demonstrating its marked therapeutic potential. With the development of neutron accelerators that can be installed in medical institutions, accelerator-based BNCT is expected to become available at several medical institutes around the world in the near future. In this commentary, from the point of view of microdosimetry, we discuss the biological effects of BNCT, especially the underlying mechanisms of cell responses. The recent development of new treatment methods that combine proton beam sources and BNCT technology is expected to contribute significantly improving the prognosis of cancer treatment in the near future. Therefore, radiobiologists in the field of BNCT and related techniques will have a significant role to play in creating synergy effects in clinical oncology.

Access

:

- Accesses

InCites™

:

パーセンタイル:100

分野:Radiology, Nuclear Medicine & Medical Imaging

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.